For patients with advanced NSCLC harboring EGFR-TKI sensitive mutations, using EGFR-TKI as first-line treatment, progression-free survival (PFS) was reported to be two to three times better than platinum-doublet chemotherapy1, 2, 3. Here, EGFR is linked to non-small cell lung carcinoma.